Trial Profile
An open-label safety study of API 31510 in a topical cream for in situ cutaneous squamous cell carcinoma (SCCIS).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2019
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Squamous cell cancer
- Focus Adverse reactions
- 24 Jul 2012 Company added in the association field as reported by ClinicalTrials.gov.
- 17 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 11 Feb 2010 Company (Berg Pharma) added as trial sponsor as reported by ClinicalTrials.gov.